The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S12-S17 , April 2006

Persistence with Bisphosphonate Treatment for Osteoporosis: Finding the Root of the Problem

  • Joyce A. Cramer, BS

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Joyce A. Cramer, BS, Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue (G7E), West Haven, Connecticut 06516-2770.
    • ,
  • Stuart Silverman, MD

      Affiliations

    • Departments of Rheumatology and Medicine, Cedars-Sinai Hospital, University of California, Los Angeles, California, USA

References 

  1. Cramer JA , Mattson RH , Prevey ML , Scheyer RD , Ouellette VL . How often is medication taken as prescribed? A novel assessment technique [published correction appears in JAMA. 1989; 262:1472] . JAMA . 1989;261:3273–3277
  2. Berg JS , Dischler J , Wagner DJ , Raia JJ , Palmer-Shevlin N . Medication compliance (a healthcare problem) . Ann Pharmacother . 1993;27(suppl):S1–S24
  3. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). ISPOR Medication Compliance and Persistence Special Interest Group (MCP) Education Working Group Issues & Methods Definitions Working Group tasks. Available at: http://www.ispor.org/sigs/medication.asp. Accessed February 27, 2006.
  4. Cramer JA . Obtaining optimal compliance with drug therapy . Manag Care . 2003;12(suppl):9–11 discussion 23-25
  5. Cramer JA . Overview of methods to measure and enhance patient compliance . In:  Cramer JA ,  Spilker B editor. Patient Compliance in Medical Practice and Clinical Trials . New York: Raven Press; 1991;p. 3–10
  6. Cramer JA . Partial medication compliance (the enigma of poor medical outcomes) . Am J Manag Care . 1995;1:45–52
  7. Cramer JA . Practical issues in medication compliance . Transplant Proc . 1999;31(4A):7S–9S
  8. Bender B , Milgrom H , Rand C . Nonadherence in asthmatic patients (is there a solution to the problem?) . Ann Allergy Asthma Immunol . 1997;79:177–185
  9. Cramer JA , Glassman M , Rienzi V . The relationship between poor medication compliance and seizures . Epilepsy Behav . 2002;3:338–342
  10. Psaty BM , Koepsell TD , Wagner EH , LoGerfo JP , Inui TS . The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers . JAMA . 1990;263:1653–1657
  11. McCombs JS , Nichol MB , Newman CM , Sclar DA . The costs of interrupting antihypertensive drug therapy in a Medicaid population . Med Care . 1994;32:214–226
  12. Silverman SL , Azria M . The analgesic role of calcitonin following osteoporotic fracture . Osteoporos Int . 2002;13:858–867
  13. Caro JJ , Ishak KJ , Huybrechts KF , Raggio G , Naujoks C . The impact of compliance with osteoporosis therapy on fracture rates in actual practice . Osteoporos Int . 2004;15:1003–1008
  14. Bonnick SL , Johnston CC , Kleerekoper M , et al.   Importance of precision in bone density measurements . J Clin Densitom . 2001;4:105–110
  15. Eastell R , Garnero P , Vrijens B , et al.   Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response (the IMPACT study) . Calcif Tissue Int . 2003;72:408; Abstract p-297
  16. Yood RA , Emani S , Reed JI , Lewis BE , Charpentier M , Lydick E . Compliance with pharmacologic therapy for osteoporosis . Osteoporos Int . 2003;14:965–968
  17. Sebalt RJ , Shane LG , Pham BZ . Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care . [abstract] J Bone Miner Res . 2004;19(suppl 1):S445
  18. Tosteson AN , Grove MR , Hammond CS , et al.   Early discontinuation of treatment for osteoporosis . Am J Med . 2003;115:209–216
  19. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. Presented at the American Society for Bone and Mineral Research (ASBMR) 23rd Annual Meeting; October 12-16, 2001; Phoenix, AZ. Abstract M406.
  20. Fosamax (alendronate sodium) tablet and oral solution [prescribing information] . Whitehouse Station, NJ: Merck & Co., Inc; 2004;
  21. Boniva (ibandronate sodium) tablets [prescribing information] . Nutley, NJ: Roche Laboratories, Inc; 2005;
  22. Actonel (risedronate sodium tablets) [prescribing information] . Kansas City, MO: Aventis Pharmaceuticals, Inc; 2004;
  23. Hamilton B , McCoy K , Taggart H . Tolerability and compliance with risedronate in clinical practice . Osteoporos Int . 2003;1:259–262
  24. Silverman SL , Greenwald M , Klein RA , Drinkwater BL . Effect of bone density information on decisions about hormone replacement therapy (a randomized trial) . Obstet Gynecol . 1997;89:321–325
  25. Clowes JA , Peel NF , Eastell R . The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis (a randomized controlled trial) . J Clin Endocrinol Metab . 2004;89:1117–1123
  26. Cramer JA , Rosenheck R . Enhancing medication compliance for people with serious mental illness . J Nerv Ment Dis . 1999;187:53–55
  27. Simon JA , Lewiecki EM , Smith ME , Petruschka RA , Wang L , Palmisano JJ . Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg (a multicenter, randomized, open-label, crossover study) . Clin Ther . 2002;24:1871–1886
  28. Cramer JA , Amonkar MM , Hebborn A , Altman RD . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis . Curr Med Res Opin . 2005;21:1453–1460
  29. Recker RR , Gallagher R , MacCosbe PE . Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women . Mayo Clin Proc . 2005;80:856–861

PII: S0002-9343(05)01198-8

doi: 10.1016/j.amjmed.2005.12.018

The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S12-S17 , April 2006

Article Tools

* Image Usage & Resolution